Daniel Zingg

[Arianna Baggiolini @BaggioliniA]

📢The Baggiolini lab has started its work thanks to the brilliant scientists @MartiBellafante, @AntoVerrillo and @rluongo90 🎉🎉🎉. Feeling grateful to have you in the lab @IOR_Bellinzona @USI_en and excited about the science we will do together 🌟

[Daniel Zingg @DanielZinggCH]

Many thanks to @CD_AACR Research Watch for highlighting our recent @Nature paper on oncogenic #fgfr2 truncation!

https://t.co/VoH7UymzZy

[Daniel Zingg @DanielZinggCH]

@trutane #FGFR2 E18 encodes the C-terminus, also open access of this article will be released soon at @Nature

[Victoria Aranda @mvicaracal]

Just last week at @nature: “Truncated FGFR2 is a clinically actionable oncogene in multiple cancers” by @jjonkers2 and colleagues https://t.co/HN5Rs8DWCl

[Arne N. Kousholt @ArneKousholt]

Exciting findinges from @DanielZinggCH, @jjonkers2 and colleagues. Highlighting that for personalized treatment approaches, we need to test the functional consequences of genetic changes in tumors. Both for tumor suppressors and oncogenes that offer treatment opportunities.

[nature @Nature]

Nature research paper: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers https://t.co/9d4u6eUc7l

[Arndt Vogel @ArndtVogel]

🔥The evolving molecular landscape of FGFR2 alterations in cancer🔥
https://t.co/YnL0JACltX

✅SNVs, EIDs, REs ➡️ E18-truncation
✅most often in #cholangiocarcinoma
👉 loss of C terminus➡️FGFR2🔥⬆️
👉multiple 💊🎯,not all respond equally ->know your target!

@myESMO #LiverTwitter

[Daniel Zingg @DanielZinggCH]

https://t.co/2D43zDeco2

#FGFR2 #Oncogene #PrecisionOncology #CancerTreatment

[Eileen P. White, PhD @EileenWhitePhD]

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers | Nature https://t.co/jUikBx1WhP

[Daniel Zingg @DanielZinggCH]

Our recent work on FGFR2 truncation and its relevance for response to FGFR targeted therapies, published in @Nature
Big thanks to @oncodeinstitute @NKI_nl @RutgersCancer @HartwigMedical @FoundationATCG @Incyte @DebiopharmNews @jjonkers2 @ShridarGanesan

https://t.co/XkDxwGI6vm

[Rutgers Cancer Institute @RutgersCancer]

Published in @Nature: Through the investigation of genetic changes in tumors, @RutgersCancer Dr. Shridar Ganesan & colleagues in collaboration with researchers from @NKI_nl & @oncodeinstitute find opportunities to improve treatment for cancer patients.

https://t.co/RZIYVBEMYC

[The Netherlands Cancer Institute @NKI_nl]

Genetic alterations in the FGFR2 gene represent a promising target for therapies, but clinical responses remained unpredictable. An international research team led by @jjonkers2 @oncodeinstitute elucidated the mechanism behind this variation in response ➡️ https://t.co/yRhzjgc0X3

[Oncode Institute @oncodeinstitute]

Promising findings in @Nature by the team of Oncode Investigator @jjonkers2: truncation of FGFR2 drives tumor formation. “Clinical trial data revealed that a good response to treatment correlates with the presence of the truncated form." Read more: https://t.co/unf1t5psgv